Synergy between Yttrium-90 ( 90 Y) and drugs was investigated. Viability of HepaRG 
Some series also report promising activity in intrahepatic cholangiocarcinoma (ICC) (2) . SIRT is used as monotherapy in primary liver cancer. However, it might be hypothesized that combination with systemic treatments may be beneficial by treating micrometastases, but also potentially by enhancing efficiency of SIRT through a synergistic effect on the primary tumor. However, these potential synergy might also lead to a risk of increased toxicity. SIRT is now being tested in metastatic colorectal cancer with concurrent chemotherapy, rather than alone (e.g. in the EPOCH trial, clinicaltrials.gov identifier NCT01483027, the FoxfireGlobal trial, NCT01721954, and the SIRFLOX trial, NCT00724503).
In advanced HCC, the only validated systemic agent is sorafenib, a tyrosine-kinase inhibitor targeting VEGFR, RAF and other kinases. However, systemic chemotherapy could be used with some evidence of efficacy. The combination of gemcitabine and oxaliplatin showed some activity in advanced HCC (3). In advanced ICC, the standard systemic treatment consists of a combination of gemcitabine and a platinum compound, but response rates are lower than 25% (4). Gemcitabine, oxaliplatin and paclitaxel have been shown to exhibit a synergistic effect with external beam radiotherapy, and some clinical applications exist, notably in pancreatic cancer (5) .
Paclitaxel is used as a radiosensitizing agent for lung cancer, and could thus be tested as potential radiosensitizing agent for primary liver cancers (6) .
Sorafenib, gemcitabine, oxaliplatin and paclitaxel would thus be relevant drugs to test in combination with SIRT for primary liver malignancies. To our knowledge, no data were reported as regard to synergy between antineoplastic drugs and 1 Y. The purpose of the study was thus to identify potential synergy between antineoplastic drugs and 90 Y in primary liver cancer cell lines.
Materials and methods

Cell lines
HepaRG was used as a hepatocarcinoma cell line, and HuCCT1 as a cholangiocarcinoma cell line (7, 8) . HepaRG cells were grown in William's E medium supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin, 100µg/mL streptomycin, 5µg/mL insulin, and 50µM hydrocortisone hemisuccinate. HuCCT1 cells were provided by the RIKEN BioResource Centre, Japan, and were grown in RPMI 1640 medium supplemented with 10% FBS, 100U/mL penicillin, 100µg/mL streptomycin and 2mM L-glutamine. HepG2 and Huh28 cells were also studied as confirmatory cell lines for hepatocarcinoma and cholangiocarcinoma, respectively.
Treatments
concentration of 5mg/mL. Paclitaxel was diluted in 0.9% Sodium Chloride at a stock concentration of 6mg/mL. Each drug was subsequently diluted in the cell culture medium.
Cell viability assay
Twenty-four hours after seeding, cells were treated with 90 Y and/or drugs for 72 hours. To measure cell viability, the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium (MTT) assay was used. The reduction of MTT into formazan salts in mitochondria of viable cells produces a coloration that could be measured by spectrophotometry, the coloration being linearly proportionate to the number of viable cells (9) . Percentages of cell viability assessed by the MTT assay were then plotted against drug concentrations and 90 Y activities to evaluate concentrations inducing a 20% to 50%-reduction in cell viability, which was used to test in combination assays.
This range of reduction of cell viability was chosen to be able to detect significant additivity or synergy: a higher reduction in cell viability in monotherapy would have led to insufficient viability in combination to distinguish synergy from additivity, and a lower reduction would have made difficult to detect any additivity. Every assay was performed in triplicate, and every experiment was repeated three times.
Combination index
A combination index (CI) was calculated to identify additive or synergistic (supraadditive) effects. CI is the ratio between the effect observed for the combination and the theoretical additive effect calculated (10) . The theoretical additive effect (TAE) was calculated by multiplying the individual effect reported with each drug used separately. CI equals to 1 denoted additivity, <1 denoted synergy and >1 denoted antagonism. Ninety-five percent confidence intervals were calculated to determine statistical significance.
Results
First, the effect on cell viability following each treatment was studied individually to select activities and concentrations suitable to identify additive or synergistic effects in combination assays (Table 1 and Figure E1 ). Higher activity for 1 (13) and sorafenib showed evidence of synergy (14) . All of these data suggest that systemic treatments may enhance efficacy of SIRT.
To date, sorafenib is the only drug tested in combination with SIRT in HCC. The rationale for such combination lies on proven activity of both treatment used as monotherapy, and on potential effects of SIRT on secretion of angiogenic factors (15) . However, the results of anti-angiogenic drugs in the tumoral vasculature may be difficult to predict, and little is known whether it would have a beneficial or a detrimental effect on tumoral uptake of microspheres. However, the results of the present study suggest that combination of sorafenib with 90 Y might have an antagonist effect on tumoral cell growth itself, but its design did not address the effect on angiogenesis.
This study has some limitations. The conclusions drawn would have been reinforced by replication in an in vivo model. It is difficult to correlate activity received in an in vitro model and activity received by the tumor in patients, but the activity received in this study are approximately 1000 times less than activity injected in an approximately 1000 times greater volume in clinics, so might probably be viewed as "in a clinical range". The study design did not address the question of angiogenesis, which is one of the mechanisms of action of sorafenib, and the interactions between SIRT, angiogenesis and hypoxia. The potential increase of toxicity could also not be studied in vitro.
In conclusion, this study supports the use of gemcitabine and oxaliplatin in combination with SIRT in HCC and ICC, but not the use of paclitaxel or sorafenib.
Clinical trial of combination of gemcitabine-platinum compounds with SIRT are warranted on HCC and ICC, and a phase II study combining glass microsphere SIRT and gemcitabine-cisplatin in ICC is now recruiting patients (Misphec Study, NCT01912053). 
